thalidomide has been researched along with Leprosy in 155 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leprosy: A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is widely used for several diseases; however, it causes malformations in embryos exposed during pregnancy." | 7.91 | The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis. ( Fraga, LR; Gomes, JDA; Kowalski, TW; Macedo, GS; Sanseverino, MTV; Schuler-Faccini, L; Vianna, FSL, 2019) |
| "We synthesized a series of novel dapsone-thalidomide hybrids (3a-i) by molecular hybridization and evaluated their potential for the treatment of type 2 leprosy reactions." | 7.80 | Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions. ( Barbieri, KP; Carlos, IZ; Chelucci, RC; Chung, MC; de Faria Fernandes Belone, A; de Melo, TR; Diório, SM; do Nascimento, DC; dos Santos, JL; Placeres, MC; Rosa, PS; Yamasaki, PR, 2014) |
| "Thalidomide is a TNF-alpha inhibitor and has been administrated for erythema nodosum leprosum (ENL, Type II leprosy reaction) which is one of leprosy reactions and can cause serious illness to patients oflepromatous pole among the immune spectrum." | 7.80 | [Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen]. ( Aoki, Y; Hatano, K; Ishida, Y; Kumano, K; Matsuki, T; Okano, Y, 2014) |
| "Thalidomide is well documented to be an effective treatment for erythema nodosum leprosum (ENL) occurring in lepromatous leprosy." | 7.66 | Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. ( Hastings, RC; Miranda, RO; Morales, MJ; Shannon, EJ, 1981) |
| "The literature concerning the use and possible mode of action of thalidomide in reactional lepromatous leprosy and in various other conditions is reviewed." | 7.66 | Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. ( Barnhill, RL; McDougall, AC, 1982) |
| "A Burmese boy being treated with dapsone (diaminodiphenylsulfone [DDS]), 100 mg daily, for lepromatous leprosy had a fatal reaction to the drug 3 weeks after therapy was started." | 7.66 | Fatal reaction to dapsone during treatment of leprosy. ( Borkowsky, W; Bullock, WE; Frey, HM; Gershon, AA, 1981) |
| "40 000 new cases of leprosy are diagnosed every year in Brazil." | 6.49 | Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. ( da Costa, LMM; de Sousa, SHC; Dias, MF; Doriqui, MJR; Leite, JCL; Maximino, CM; Morelo, EF; Sanseverino, MTV; Schüler-Faccini, L; Vianna, FSL, 2013) |
| "Thalidomide has been used to treat ENL since the 1960s." | 6.41 | Thalidomide in the treatment of leprosy. ( Kook, KA; Resztak, KE; Scheffler, MA; Stirling, DI; Teo, S; Thomas, SD; Zeldis, JB, 2002) |
| "Thalidomide, used to treat erythema nodosum leprosum (ENL), is associated with severe adverse events (AEs) and is highly teratogenic." | 5.51 | Adverse events in patients with leprosy on treatment with thalidomide. ( Carvalho, GO; Drummond, PLM; Pádua, CAM; Santos, RMMD, 2019) |
| "Thalidomide is an effective treatment for ENL but not RR." | 5.33 | Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction. ( Abebe, M; Aseffa, A; Bizuneh, E; Mulugeta, W; Shannon, EJ; Tadesse, A, 2006) |
| "As thalidomide is an effective treatment for ENL, this study assessed the effect of this drug on these phenomena." | 5.32 | Thalidomide does not modify the ability of cells in leprosy patients to incorporate [3H]-thymidine when incubated with M. leprae antigens. ( Sandoval, F; Shannon, EJ; Tadesse, A; Taye, E, 2003) |
| "But eventually due to recurrence these cases had to be put back on steroids because of easier availability." | 5.26 | Treatment with thalidomide in steroid dependency and neuritis. ( Theophilus, S, 1980) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "A population pharmacokinetic (PPK) model to describe the pharmacokinetics of thalidomide in different patient populations was developed using data pooled from healthy subjects and patients with Hansen's disease, human immunodeficiency virus (HIV), and multiple myeloma (MM)." | 3.96 | Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics. ( Chen, N; Gaudy, A; Hwang, R; Palmisano, M, 2020) |
| "Thalidomide is widely used for several diseases; however, it causes malformations in embryos exposed during pregnancy." | 3.91 | The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis. ( Fraga, LR; Gomes, JDA; Kowalski, TW; Macedo, GS; Sanseverino, MTV; Schuler-Faccini, L; Vianna, FSL, 2019) |
| "We analyzed the frequency of births with phenotypes consistent with thalidomide embryopathy (TEP) and correlated this with the distribution of thalidomide and the prevalence of leprosy between 2005 and 2010 in Brazil." | 3.81 | Pharmacoepidemiology and thalidomide embryopathy surveillance in Brazil. ( Camey, SA; de Lyra Rabello Neto, D; de Oliveira, MZ; Lopez-Camelo, J; Morelo, EF; Sales Luiz Vianna, F; Sanseverino, MT; Schuler-Faccini, L, 2015) |
| "Thalidomide is a TNF-alpha inhibitor and has been administrated for erythema nodosum leprosum (ENL, Type II leprosy reaction) which is one of leprosy reactions and can cause serious illness to patients oflepromatous pole among the immune spectrum." | 3.80 | [Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen]. ( Aoki, Y; Hatano, K; Ishida, Y; Kumano, K; Matsuki, T; Okano, Y, 2014) |
| "We synthesized a series of novel dapsone-thalidomide hybrids (3a-i) by molecular hybridization and evaluated their potential for the treatment of type 2 leprosy reactions." | 3.80 | Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions. ( Barbieri, KP; Carlos, IZ; Chelucci, RC; Chung, MC; de Faria Fernandes Belone, A; de Melo, TR; Diório, SM; do Nascimento, DC; dos Santos, JL; Placeres, MC; Rosa, PS; Yamasaki, PR, 2014) |
| "Thalidomide was a widely used drug in the late 1950s and early 1960s for the treatment of nausea in pregnant women." | 3.77 | Thalidomide: the tragedy of birth defects and the effective treatment of disease. ( Kim, JH; Scialli, AR, 2011) |
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| "Thalidomide, mainly used for the treatment of leprosy, is a current teratogen in South America, and it is reasonable to assume that at present this situation is affecting many births in underdeveloped countries." | 3.69 | Thalidomide, a current teratogen in South America. ( Ashton-Prolla, P; Barreda-Mejia, E; Brunoni, D; Castilla, EE; Cavalcanti, DP; Correa-Neto, J; Delgadillo, JL; Dutra, MG; Felix, T; Giraldo, A; Juarez, N; Lopez-Camelo, JS; Nazer, J; Orioli, IM; Paz, JE; Pessoto, MA; Pina-Neto, JM; Quadrelli, R; Rittler, M; Rueda, S; Saltos, M; Sánchez, O; Schüler, L, 1996) |
| "Thalidomide is the drug of choice in the erythema nodosum leprosum (ENL) type of lepra reaction." | 3.67 | Thalidomide--effect on T cell subsets as a possible mechanism of action. ( Baranda, ML; González-Amaro, R; Loredo, CE; Moncada, B; Urbina, R, 1985) |
| "Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug." | 3.66 | [Thalidomide in dermatology]. ( Hunziker, T; Krebs, A, 1983) |
| "Thalidomide is well documented to be an effective treatment for erythema nodosum leprosum (ENL) occurring in lepromatous leprosy." | 3.66 | Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. ( Hastings, RC; Miranda, RO; Morales, MJ; Shannon, EJ, 1981) |
| "The literature concerning the use and possible mode of action of thalidomide in reactional lepromatous leprosy and in various other conditions is reviewed." | 3.66 | Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. ( Barnhill, RL; McDougall, AC, 1982) |
| "A Burmese boy being treated with dapsone (diaminodiphenylsulfone [DDS]), 100 mg daily, for lepromatous leprosy had a fatal reaction to the drug 3 weeks after therapy was started." | 3.66 | Fatal reaction to dapsone during treatment of leprosy. ( Borkowsky, W; Bullock, WE; Frey, HM; Gershon, AA, 1981) |
| " Lucio's phenomenon is a syndrome distinct from erythema nodosum leprosum as indicated by an absence of fever, leukocytosis and tenderness, a failure to respond to thalidomide, and a restriction to patients with diffuse nonnodular lepromatous leprosy." | 3.66 | Lucio's phenomenon and diffuse nonnodular lepromatous leprosy. ( Levan, NE; Rea, TH, 1978) |
| " Reactive episodes continue to be a serious complication, but the availability of thalidomide to control erythema nodosum leprosum has markedly improved the prognosis." | 3.65 | The diagnosis and treatment of leprosy. ( Jacobson, RR; Trautman, JR, 1976) |
| "This analysis allows us to think beyond the safe use of thalidomide, but the safety provided by any type of monitoring system." | 2.82 | Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety? ( de Jesus, SM; Leite, SN; Santana, RS, 2022) |
| "Prednisolone was evidently preferred for treatment of ENL in Chingleput, whereas thalidomide was preferred in Bamako." | 2.68 | Response to treatment by multidrug regimens in the THELEP controlled clinical drug trials. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Train ( , 1996) |
| "A leprosy reaction resembling Sweet syndrome was first described in 1987." | 2.66 | Type 2 leprosy reaction resembling Sweet syndrome: Review of new and published cases. ( Chavez-Alvarez, S; Gomez-Flores, M; Herz-Ruelas, M; Ocampo-Candiani, J, 2020) |
| "40 000 new cases of leprosy are diagnosed every year in Brazil." | 2.49 | Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. ( da Costa, LMM; de Sousa, SHC; Dias, MF; Doriqui, MJR; Leite, JCL; Maximino, CM; Morelo, EF; Sanseverino, MTV; Schüler-Faccini, L; Vianna, FSL, 2013) |
| "Leprosy is not eliminated." | 2.43 | Treatment of leprosy: science or politics? ( Naafs, B, 2006) |
| "Thalidomide has been used to treat ENL since the 1960s." | 2.41 | Thalidomide in the treatment of leprosy. ( Kook, KA; Resztak, KE; Scheffler, MA; Stirling, DI; Teo, S; Thomas, SD; Zeldis, JB, 2002) |
| "Thalidomide, used to treat erythema nodosum leprosum (ENL), is associated with severe adverse events (AEs) and is highly teratogenic." | 1.51 | Adverse events in patients with leprosy on treatment with thalidomide. ( Carvalho, GO; Drummond, PLM; Pádua, CAM; Santos, RMMD, 2019) |
| "Thalidomide, an effective treatment for ENL, inhibited this neutrophil recruitment pathway." | 1.36 | Integrated pathways for neutrophil recruitment and inflammation in leprosy. ( Burdick, A; Carbone, RJ; Damoiseaux, R; Lee, DJ; Li, H; Modlin, RL; Ochoa, MT; Rea, TH; Sarno, EN; Tanaka, M, 2010) |
| "Thalidomide is an effective treatment for ENL but not RR." | 1.33 | Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction. ( Abebe, M; Aseffa, A; Bizuneh, E; Mulugeta, W; Shannon, EJ; Tadesse, A, 2006) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| "As thalidomide is an effective treatment for ENL, this study assessed the effect of this drug on these phenomena." | 1.32 | Thalidomide does not modify the ability of cells in leprosy patients to incorporate [3H]-thymidine when incubated with M. leprae antigens. ( Sandoval, F; Shannon, EJ; Tadesse, A; Taye, E, 2003) |
| "Thalidomide also did not inhibit metabolism of CYP-specific substrates and therefore any interactions with other drugs that are metabolized by the same enzyme system are unlikely." | 1.31 | Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. ( Kook, KA; O'Brien, K; Sabourin, PJ; Teo, SK; Thomas, SD, 2000) |
| "Thalidomide is a drug associated with devastating side effects." | 1.30 | Thalidomide's long and winding road. ( Hanna, L, 1998) |
| "We have treated three leprosy patients suffering from chronic, steroid-dependent erythema nodosum leprosum (ENL) with cyclosporine A (CsA)." | 1.27 | Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. ( Harnisch, JP; Miller, RA; Rea, TH; Shen, JY, 1987) |
| "But eventually due to recurrence these cases had to be put back on steroids because of easier availability." | 1.26 | Treatment with thalidomide in steroid dependency and neuritis. ( Theophilus, S, 1980) |
| " The initial dosage of either of the drugs was 300 mg daily administered in divided doses of 100 mg three times a day." | 1.26 | Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine. ( Girdhar, A; Ramu, G, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 94 (60.65) | 18.7374 |
| 1990's | 19 (12.26) | 18.2507 |
| 2000's | 17 (10.97) | 29.6817 |
| 2010's | 19 (12.26) | 24.3611 |
| 2020's | 6 (3.87) | 2.80 |
| Authors | Studies |
|---|---|
| Yamasaki, PR | 1 |
| do Nascimento, DC | 1 |
| Chelucci, RC | 1 |
| de Faria Fernandes Belone, A | 1 |
| Rosa, PS | 1 |
| Diório, SM | 1 |
| de Melo, TR | 1 |
| Barbieri, KP | 1 |
| Placeres, MC | 1 |
| Carlos, IZ | 1 |
| Chung, MC | 1 |
| dos Santos, JL | 1 |
| Bera, S | 1 |
| Mondal, D | 1 |
| Gaudy, A | 1 |
| Hwang, R | 1 |
| Palmisano, M | 1 |
| Chen, N | 1 |
| da Silva, CO | 1 |
| Dias, AA | 1 |
| da Costa Nery, JA | 1 |
| de Miranda Machado, A | 1 |
| Ferreira, H | 1 |
| Rodrigues, TF | 1 |
| Sousa Santos, JP | 1 |
| Nadaes, NR | 1 |
| Sarno, EN | 4 |
| Saraiva, EM | 1 |
| Schmitz, V | 1 |
| Pessolani, MCV | 1 |
| Walker, SL | 1 |
| Ribeiro, SLE | 1 |
| Pereira, HLA | 1 |
| Boechat, AL | 1 |
| Silva, NP | 1 |
| Sato, EI | 1 |
| das Graças Souza Cunha, M | 1 |
| de Souza Passos, LF | 1 |
| Dos-Santos, MC | 1 |
| Chavez-Alvarez, S | 1 |
| Herz-Ruelas, M | 1 |
| Ocampo-Candiani, J | 1 |
| Gomez-Flores, M | 1 |
| Jesus, SM | 1 |
| Santana, RS | 2 |
| Leite, SN | 2 |
| de Jesus, SM | 1 |
| Cerqueira, SRPS | 1 |
| Deps, PD | 1 |
| Cunha, DV | 1 |
| Bezerra, NVF | 1 |
| Barroso, DH | 1 |
| Pinheiro, ABS | 1 |
| Pillegi, GS | 1 |
| Repsold, TAR | 1 |
| Kurizky, PS | 1 |
| Collin, SM | 1 |
| Gomes, CM | 1 |
| Labuda, SM | 1 |
| Schieffelin, JS | 1 |
| Shaffer, JG | 1 |
| Stryjewska, BM | 1 |
| Kar, HK | 1 |
| Gupta, L | 1 |
| Drummond, PLM | 1 |
| Santos, RMMD | 1 |
| Carvalho, GO | 1 |
| Pádua, CAM | 1 |
| Gomes, JDA | 1 |
| Kowalski, TW | 2 |
| Fraga, LR | 2 |
| Macedo, GS | 1 |
| Sanseverino, MTV | 2 |
| Schuler-Faccini, L | 4 |
| Vianna, FSL | 2 |
| Leite, JCL | 1 |
| de Sousa, SHC | 1 |
| da Costa, LMM | 1 |
| Dias, MF | 1 |
| Morelo, EF | 2 |
| Doriqui, MJR | 1 |
| Maximino, CM | 1 |
| Matsuki, T | 1 |
| Okano, Y | 1 |
| Aoki, Y | 1 |
| Ishida, Y | 1 |
| Hatano, K | 1 |
| Kumano, K | 1 |
| Sales Luiz Vianna, F | 2 |
| de Oliveira, MZ | 1 |
| Sanseverino, MT | 2 |
| de Lyra Rabello Neto, D | 1 |
| Lopez-Camelo, J | 1 |
| Camey, SA | 1 |
| Rahul, N | 1 |
| Sanjay, KS | 1 |
| Singh, S | 1 |
| Watts, G | 1 |
| Millrine, D | 1 |
| Kishimoto, T | 1 |
| Aires, NB | 1 |
| Refkalefsky Loureiro, W | 1 |
| Villela, MA | 1 |
| Sakai Valente, NY | 1 |
| Trindade, MA | 1 |
| Lee, DJ | 1 |
| Li, H | 1 |
| Ochoa, MT | 1 |
| Tanaka, M | 1 |
| Carbone, RJ | 1 |
| Damoiseaux, R | 1 |
| Burdick, A | 1 |
| Rea, TH | 5 |
| Modlin, RL | 1 |
| Kim, JH | 1 |
| Scialli, AR | 1 |
| Hernandez, Mde O | 1 |
| Fulco, Tde O | 1 |
| Pinheiro, RO | 1 |
| Pereira, Rde M | 1 |
| Redner, P | 1 |
| Lopes, UG | 1 |
| Sampaio, EP | 2 |
| Yamaguchi, S | 1 |
| Yamamoto, Y | 1 |
| Hosokawa, A | 1 |
| Hagiwara, K | 1 |
| Uezato, H | 1 |
| Takahashi, K | 1 |
| Silverman, WA | 1 |
| Teo, S | 1 |
| Resztak, KE | 1 |
| Scheffler, MA | 1 |
| Kook, KA | 2 |
| Zeldis, JB | 1 |
| Stirling, DI | 1 |
| Thomas, SD | 2 |
| Teles, RM | 1 |
| Moraes, MO | 1 |
| Geraldo, NT | 1 |
| Salles, AM | 1 |
| Crawford, CL | 7 |
| Gordon, JN | 1 |
| Goggin, PM | 1 |
| Tadesse, A | 2 |
| Taye, E | 1 |
| Sandoval, F | 1 |
| Shannon, EJ | 4 |
| Pannikar, V | 1 |
| Pereira, GF | 1 |
| Lockwood, D | 1 |
| Bryceson, A | 1 |
| Naafs, B | 3 |
| Aranda, J | 1 |
| Hoang, MP | 1 |
| Cohen, JB | 1 |
| Ganapati, R | 1 |
| Pai, VV | 1 |
| Abebe, M | 1 |
| Bizuneh, E | 1 |
| Mulugeta, W | 1 |
| Aseffa, A | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Grosshans, E | 2 |
| Illy, G | 1 |
| Nielsen, H | 1 |
| Bennike, T | 1 |
| Belaube, P | 1 |
| Garcin, G | 1 |
| Marchand, JP | 1 |
| Privat, Y | 1 |
| Levis, WR | 3 |
| Yoshida, T | 1 |
| Brazin, SA | 1 |
| de Almeida Neto, E | 1 |
| Hunziker, T | 1 |
| Krebs, A | 1 |
| Sheskin, J | 12 |
| Mückter, H | 1 |
| Frankus, E | 1 |
| Rajan, MA | 1 |
| Rajagopalan, MS | 1 |
| Joseph, M | 1 |
| Miranda, RO | 1 |
| Morales, MJ | 1 |
| Hastings, RC | 3 |
| Mshana, RN | 1 |
| Haregewoin, A | 1 |
| Belehu, A | 1 |
| Barnhill, RL | 1 |
| McDougall, AC | 1 |
| Miyachi, Y | 1 |
| Ozaki, M | 1 |
| Uchida, K | 1 |
| Niwa, Y | 1 |
| Theophilus, S | 1 |
| Frey, HM | 1 |
| Gershon, AA | 1 |
| Borkowsky, W | 1 |
| Bullock, WE | 2 |
| Jopling, WH | 2 |
| Gorodetsky, R | 1 |
| Weinreb, A | 1 |
| Loewinger, E | 1 |
| dos Santos Júnior, MF | 1 |
| Lombardi, C | 1 |
| Belda, W | 2 |
| Samsoen, M | 1 |
| Basset, A | 1 |
| Cutler, J | 1 |
| Asscher, W | 1 |
| Sticht-Groh, V | 1 |
| Bretzel, G | 1 |
| Castilla, EE | 1 |
| Ashton-Prolla, P | 1 |
| Barreda-Mejia, E | 1 |
| Brunoni, D | 1 |
| Cavalcanti, DP | 1 |
| Correa-Neto, J | 1 |
| Delgadillo, JL | 1 |
| Dutra, MG | 1 |
| Felix, T | 1 |
| Giraldo, A | 1 |
| Juarez, N | 1 |
| Lopez-Camelo, JS | 1 |
| Nazer, J | 1 |
| Orioli, IM | 1 |
| Paz, JE | 1 |
| Pessoto, MA | 1 |
| Pina-Neto, JM | 1 |
| Quadrelli, R | 1 |
| Rittler, M | 1 |
| Rueda, S | 1 |
| Saltos, M | 1 |
| Sánchez, O | 1 |
| Schüler, L | 1 |
| Velázquez de Castro y Sagarra, A | 1 |
| López Bueno, R | 1 |
| Gómez Jiménez, G | 1 |
| Vides, EA | 1 |
| Cabrera, A | 1 |
| Ahern, KP | 1 |
| Miller, MT | 1 |
| Strömland, K | 1 |
| Teo, SK | 1 |
| Sabourin, PJ | 1 |
| O'Brien, K | 1 |
| Hanna, L | 1 |
| Highleyman, L | 1 |
| Jolliffe, DS | 1 |
| Faber, WR | 1 |
| Leiker, DL | 1 |
| Cormane, RH | 1 |
| Yaar, I | 1 |
| Ramu, G | 3 |
| Girdhar, A | 1 |
| Taylor, CR | 1 |
| Goihman-Yahr, M | 1 |
| Convit, J | 2 |
| Rodríguez-Ochoa, G | 1 |
| Aranzazu, N | 1 |
| Villalba-Pimentel, L | 1 |
| Ocanto, A | 1 |
| de Gómez, ME | 1 |
| Levan, NE | 2 |
| Jacobson, RR | 2 |
| Trautman, JR | 2 |
| Iyer, CG | 3 |
| Ramanujam, K | 3 |
| Browne, SG | 6 |
| Sagher, F | 4 |
| Pfaltzgraff, RE | 1 |
| Schuller-Levis, G | 1 |
| Harris, D | 1 |
| Cutler, E | 1 |
| Meeker, HC | 1 |
| Haubenstock, H | 1 |
| Miller, RA | 1 |
| Shen, JY | 1 |
| Harnisch, JP | 1 |
| Loretti, A | 1 |
| Barchi, E | 1 |
| Neelamkavil, P | 1 |
| Gad, SM | 1 |
| Krotoski, WA | 1 |
| Moncada, B | 1 |
| Baranda, ML | 1 |
| González-Amaro, R | 1 |
| Urbina, R | 1 |
| Loredo, CE | 1 |
| Koch, HP | 1 |
| Levy, L | 1 |
| Fasal, P | 1 |
| Freedman, RI | 1 |
| Swift, TR | 1 |
| Sabin, TD | 1 |
| Contreras Duenas, F | 1 |
| Luger, A | 1 |
| Waters, MF | 3 |
| Gibbels, E | 1 |
| Scheid, W | 1 |
| Wieck, HH | 1 |
| Kinzel, W | 1 |
| Gajl-Peczalska, KJ | 1 |
| Lim, SD | 1 |
| Good, RA | 1 |
| Rohde, R | 1 |
| Coudert, J | 1 |
| Lu, HT | 1 |
| Antia, NH | 1 |
| Pearson, JM | 2 |
| Vedagiri, M | 1 |
| Languillon, J | 3 |
| Tarabini-Castellani, G | 1 |
| De las Aguas, JT | 1 |
| Bechelli, LM | 2 |
| Uemura, K | 1 |
| Martinez Dominguez, V | 2 |
| Sundaresan, T | 1 |
| Cazort, RJ | 1 |
| Duperrat, B | 2 |
| Puissant, A | 2 |
| David, V | 1 |
| Saurat, JM | 1 |
| Merklen, FP | 2 |
| Cottenot, F | 2 |
| Pennec, J | 1 |
| Vernant, JC | 1 |
| Buzacoux, J | 1 |
| Manzoli, S | 1 |
| Jordy, CF | 1 |
| Pettit, JH | 1 |
| Tarabini, G | 1 |
| de Souza Lima, L | 1 |
| Tolentino, JG | 1 |
| Opromolla, DV | 1 |
| Lima, LS | 1 |
| Marques, MB | 1 |
| Schuppli, R | 1 |
| Latapí, F | 1 |
| Saúl, A | 1 |
| Gómez-Vidal, M | 1 |
| Zauberman, H | 1 |
| Nelson, DS | 1 |
| Nelson, M | 1 |
| Thurston, JM | 1 |
| Jonquières, ED | 1 |
| Mosto, SJ | 1 |
| Brusco, CM | 1 |
| Netto, LS | 1 |
| Pringuet, R | 1 |
| Revuz, J | 1 |
| Lauret, P | 1 |
| Klein, JM | 1 |
| Giraudeau, P | 1 |
| La Rosa, P | 1 |
| Casciano, A | 1 |
| Baccaredda-Boy, A | 1 |
| Bertamino, R | 1 |
| DeFeo, C | 1 |
| Hogerzeil, LM | 1 |
| Simons, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL[NCT03775460] | 550 participants (Anticipated) | Interventional | 2023-01-15 | Recruiting | |||
| A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer[NCT00001446] | Phase 2 | 64 participants | Interventional | 1995-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
23 reviews available for thalidomide and Leprosy
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Type 2 leprosy reaction resembling Sweet syndrome: Review of new and published cases.
Topics: Anti-Bacterial Agents; Humans; Leprostatic Agents; Leprosy; Male; Sweet Syndrome; Thalidomide | 2020 |
The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.
Topics: Abnormalities, Drug-Induced; Brazil; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; | 2020 |
Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety?
Topics: Brazil; Drug Monitoring; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; Leprosy, Lep | 2022 |
Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings.
Topics: Brazil; Endemic Diseases; Erythema Nodosum; Female; Fetal Diseases; Humans; Hypnotics and Sedatives; | 2013 |
A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Humans; Leprosy; Models, Molecular; Thalidom | 2017 |
Thalidomide in the treatment of leprosy.
Topics: Drug Therapy, Combination; Erythema Nodosum; Humans; Incidence; Leprostatic Agents; Leprosy; Leprosy | 2002 |
Thalidomide and its derivatives: emerging from the wilderness.
Topics: Adjuvants, Immunologic; Cachexia; Crohn Disease; Graft vs Host Disease; Hematologic Neoplasms; Human | 2003 |
Treatment of leprosy: science or politics?
Topics: Attitude to Health; Erythema Nodosum; Health Knowledge, Attitudes, Practice; Health Policy; Humans; | 2006 |
Thalidomide therapy for inflammatory dermatoses.
Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity | 1984 |
Treatment of leprosy in the United States.
Topics: Adrenal Cortex Hormones; Drug Resistance; Drug Therapy, Combination; Female; Humans; Immunotherapy; | 1984 |
Leprosy (Hansen's disease).
Topics: Clofazimine; Dapsone; Ear Deformities, Acquired; Humans; Leprosy; Mouth Diseases; Nose Deformities, | 1982 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy; Nervous System Diseases; Peripheral Nervous System; Thalidomide | 1994 |
[Leprosy--current aspects of a disease from biblical times].
Topics: Bible; Clofazimine; Glucocorticoids; History, Ancient; Humans; Immunotherapy; Leprostatic Agents; Le | 1995 |
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A | 1996 |
Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.
Topics: Eye Abnormalities; Female; History, 20th Century; HIV Infections; Humans; Infant, Newborn; Leprosy; | 1999 |
Leprosy reactional states and their treatment.
Topics: Antigen-Antibody Complex; Clofazimine; Dapsone; Humans; Immunity, Cellular; Leprosy; Prednisolone; T | 1977 |
Thalidomide and congeners as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Gastrointestinal Diseases; Humans; Immunos | 1985 |
The evaluation of present antileprosy compounds.
Topics: Animals; Anti-Bacterial Agents; Clinical Trials as Topic; Dapsone; Disease Models, Animal; Drug Resi | 1969 |
Summary of recent abstracts. 8. Leprosy.
Topics: Animals; Antibody Formation; BCG Vaccine; Dapsone; Disease Models, Animal; Guinea Pigs; Humans; Lepr | 1970 |
[Leprosy research].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Diagnosis, Differential; Ethambutol; | 1971 |
Summary of recent abstracts. 8. Leprosy.
Topics: Animals; Facial Paralysis; Genetics, Microbial; Hepatitis B Antigens; Humans; Leprosy; Mice; Mycobac | 1972 |
Summary of recent abstracts. 8. Leprosy.
Topics: Animals; Dapsone; Disease Models, Animal; Humans; Leprosy; Mice; Phenazines; Thalidomide | 1971 |
14 trials available for thalidomide and Leprosy
| Article | Year |
|---|---|
Comparative efficacy of four treatment regimens in Type 2 Leprosy Reactions (Prednisolone alone, Thalidomide alone, Prednisolone plus Thalidomide and Prednisolone plus Clofazimine).
Topics: Adult; Clofazimine; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Longitud | 2016 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
[Comparative study of the therapeutic activity of glutamic acid phthalimide and the therapeutic activity of triamcinolone in the treatment of Hansen's reaction of Virchowian Leprosy].
Topics: Clinical Trials as Topic; Double-Blind Method; Erythema Nodosum; Humans; Leprosy; Thalidomide; Triam | 1981 |
Response to treatment by multidrug regimens in the THELEP controlled clinical drug trials. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Train
Topics: Drug Therapy, Combination; Glucocorticoids; Humans; Leprostatic Agents; Leprosy; Mycobacterium lepra | 1996 |
Effect of zafirlukast on leprosy reactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clofazimine; Cohort Studies; D | 1999 |
[Therapeutic experience on the effect of thalidomidomide on lepra reaction].
Topics: Aspirin; Climate; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Israel; Lepro | 1975 |
Open trial with clofazimine in the management of recurrent lepra reaction and of sulphone sensitive cases: a preliminary report.
Topics: Adult; Clinical Trials as Topic; Clofazimine; Drug Hypersensitivity; Humans; Leprosy; Male; Sulfones | 1975 |
The evaluation of present antileprosy compounds.
Topics: Animals; Anti-Bacterial Agents; Clinical Trials as Topic; Dapsone; Disease Models, Animal; Drug Resi | 1969 |
An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum.
Topics: Adrenocorticotropic Hormone; Adult; Chronic Disease; Clinical Trials as Topic; Erythema Nodosum; Hum | 1971 |
[Treatment of the leprosy reaction with thalidomide. (A double-blind study). Preliminary report].
Topics: Clinical Trials as Topic; Humans; Leprosy; Placebos; Thalidomide | 1966 |
Treatment of moderately severe erythema nodosum leprosum with thalidomide--a double-blind controlled trial.
Topics: Clinical Trials as Topic; Erythema Nodosum; Female; Humans; Leprosy; Male; Placebos; Thalidomide | 1969 |
[Current state of thalidomide treatment of leprosy and leprosy reaction].
Topics: Clinical Trials as Topic; Dapsone; Drug Synergism; Female; Glucocorticoids; Humans; Leprosy; Male; P | 1970 |
WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.
Topics: Acute Disease; Adolescent; Adult; Aspirin; Clinical Trials as Topic; Humans; Leprosy; Male; Middle A | 1971 |
[Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme)].
Topics: Clinical Trials as Topic; Erythema Multiforme; Erythema Nodosum; Female; Humans; Lepromin; Leprosy; | 1966 |
119 other studies available for thalidomide and Leprosy
| Article | Year |
|---|---|
Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Dapsone; Dose-Response Relationship, Drug; Humans; Lepros | 2014 |
Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Fema | 2020 |
Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Extracellular Traps; Female; Humans; Immunity, | 2019 |
New therapeutics for leprosy.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 2020 |
Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; beta 2-Glycoprotein I; Enzyme-Link | 2019 |
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study.
Topics: Adrenal Cortex Hormones; BCG Vaccine; Brazil; Clofazimine; Cohort Studies; COVID-19; COVID-19 Drug T | 2021 |
Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clofazimine; Cross-Over Studies; Drug Therapy, Co | 2017 |
Adverse events in patients with leprosy on treatment with thalidomide.
Topics: Cross-Sectional Studies; Educational Status; Female; Humans; Leprostatic Agents; Leprosy; Male; Midd | 2019 |
The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis.
Topics: Abnormalities, Multiple; Acetyltransferases; Brazil; Cell Line; Chromosomal Proteins, Non-Histone; C | 2019 |
[Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen].
Topics: Adult; Aged; Asian People; Drug Administration Schedule; Erythema Nodosum; Female; Humans; Japan; Le | 2014 |
Pharmacoepidemiology and thalidomide embryopathy surveillance in Brazil.
Topics: Abnormalities, Drug-Induced; Brazil; Drug Prescriptions; Female; Humans; Infant, Newborn; Leprosy; P | 2015 |
Effectiveness of Methotrexate in prednisolone and thalidomide resistant cases of Type 2 lepra reaction: report on three cases.
Topics: Adult; Drug Resistance, Bacterial; Humans; Leprosy; Male; Methotrexate; Mycobacterium lepraemurium; | 2015 |
Thomas Herald Rea.
Topics: Dermatology; History, 20th Century; History, 21st Century; Humans; Leprostatic Agents; Leprosy; Male | 2016 |
The impact of thalidomide use in birth defects in Brazil.
Topics: Abnormalities, Multiple; Brazil; Congenital Abnormalities; Fetal Diseases; Humans; Leprosy; Teratoge | 2017 |
Sweet's syndrome type leprosy reaction.
Topics: Female; Humans; Leprosy; Male; Sweet Syndrome; Thalidomide | 2009 |
Integrated pathways for neutrophil recruitment and inflammation in leprosy.
Topics: Cluster Analysis; E-Selectin; Gene Expression Profiling; Humans; Inflammation; Interferon-gamma; Int | 2010 |
Thalidomide: the tragedy of birth defects and the effective treatment of disease.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Ect | 2011 |
Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway and lower cytokine response.
Topics: Active Transport, Cell Nucleus; Cell Nucleus; DNA; Enzyme Activation; Female; Humans; Leprostatic Ag | 2011 |
Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy.
Topics: Adrenal Cortex Hormones; Cyclosporine; Humans; Leprostatic Agents; Leprosy; Male; Middle Aged; Pulmo | 2012 |
The schizophrenic career of a "monster drug".
Topics: Animals; Drug Evaluation, Preclinical; Germany, West; History, 20th Century; Humans; Hypnotics and S | 2002 |
Differential TNFalpha mRNA regulation detected in the epidermis of leprosy patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cytokines; Dermis; Epidermis; Female; Humans; Intercellular A | 2002 |
The schizophrenic career of a "monster drug".
Topics: Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy; Leprosy, Lepromatous; Nervous System | 2003 |
Thalidomide does not modify the ability of cells in leprosy patients to incorporate [3H]-thymidine when incubated with M. leprae antigens.
Topics: Adolescent; Adult; Aged; Antigens, Bacterial; Cell Division; Female; Humans; Leprostatic Agents; Lep | 2003 |
The return of thalidomide: new uses and renewed concerns.
Topics: Abnormalities, Drug-Induced; Global Health; Health Policy; Humans; Leprostatic Agents; Leprosy; Tera | 2003 |
On thalidomide and WHO policies.
Topics: Abnormalities, Drug-Induced; Global Health; Health Policy; Humans; Leprostatic Agents; Leprosy; Thal | 2003 |
The return of thalidomide: new uses and renewed concerns--reply.
Topics: Clinical Trials as Topic; Humans; Leprostatic Agents; Leprosy; Thalidomide | 2003 |
The return of thalidomide: new uses and renewed concerns--reply.
Topics: Global Health; Health Policy; Humans; Leprostatic Agents; Leprosy; Thalidomide; World Health Organiz | 2003 |
Shiny red-brown papules in a 21-year-old man. Histoid leprosy.
Topics: Adult; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Face; Humans; Lepro | 2004 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction.
Topics: Adolescent; Adult; Aged; Antigens, Bacterial; Cell Proliferation; Cell Survival; Cells, Cultured; Er | 2006 |
Thalidomide enhances defective monocyte function in lepromatous leprosy.
Topics: Adult; Erythema Nodosum; Humans; Leprosy; Male; Monocytes; Thalidomide | 1984 |
[Should thalidomide be rehabilitated?].
Topics: Chemical Phenomena; Chemistry; Humans; Leprosy; Photosensitivity Disorders; Thalidomide | 1983 |
Serum macrophage migration inhibition activity in patients with leprosy.
Topics: Dapsone; Dinitrochlorobenzene; Humans; Hypersensitivity, Delayed; Leprosy; Macrophage Migration-Inhi | 1982 |
[Thalidomide in dermatology].
Topics: Animals; Female; Guinea Pigs; Humans; Immunity; Leprosy; Lupus Erythematosus, Discoid; Male; Mice; N | 1983 |
[Supidimide, a non-teratogenic thalidomide analog for the treatment of leprosy reaction?].
Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; Mal | 1983 |
A clinical study of thalidomide comparing pre-treatment and post-treatment reactional episodes and corticosteroid requirements.
Topics: Adolescent; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprosy; Male; Prednisolone; Thalid | 1983 |
[Limitations, within narrow indications, in the administration of thalidomide].
Topics: Humans; Leprosy; Lupus Erythematosus, Discoid; Thalidomide | 1983 |
Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy.
Topics: Animals; Complement C3; Erythema Nodosum; Female; Hemagglutinins; Hemolytic Plaque Technique; Immuno | 1981 |
Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations.
Topics: Antibodies, Monoclonal; Dapsone; Erythema Nodosum; Humans; Leprosy; Lymphocyte Activation; Mycobacte | 1982 |
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions.
Topics: Anti-Inflammatory Agents; Chemotaxis, Leukocyte; Humans; Immunosuppressive Agents; Leprosy; Lupus Er | 1982 |
Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes.
Topics: Cells, Cultured; Depression, Chemical; Erythema Nodosum; Humans; Hydrogen Peroxide; Hydroxides; Lepr | 1982 |
Treatment with thalidomide in steroid dependency and neuritis.
Topics: Adrenal Cortex Hormones; Erythema Nodosum; Humans; Leprosy; Male; Neuritis; Recurrence; Thalidomide | 1980 |
Fatal reaction to dapsone during treatment of leprosy.
Topics: Adolescent; Dapsone; Erythema; Humans; Leprosy; Male; Skin; Thalidomide | 1981 |
Thalidomide.
Topics: Humans; Leprosy; Thalidomide | 1981 |
Iron content of skin before and after thalidomide treatment of lepra reaction. A preliminary report.
Topics: Adult; Copper; Female; Humans; Iron; Leprosy; Male; Middle Aged; Skin; Spectrometry, X-Ray Emission; | 1981 |
[Thalidomide: a review of the literature].
Topics: Animals; Chemical Phenomena; Chemistry; Erythema Nodosum; Humans; Leprosy; Rats; Skin Diseases; Tera | 1981 |
Kellersberger Memorial Lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues.
Topics: Animals; Anti-Inflammatory Agents; Erythema Nodosum; Immunosuppressive Agents; Leprosy; Mice; Rats; | 1980 |
[Thalidomide in the treatment of discoid lupus erythematosus (D.L.E.) (author's transl)].
Topics: Adolescent; Adult; Aged; Chemical Phenomena; Chemistry; Chronic Disease; Female; Humans; Immunosuppr | 1980 |
Thalidomide revisited.
Topics: Abnormalities, Multiple; Brazil; Drug Utilization; Female; Humans; Leprosy; Thalidomide | 1994 |
Safety of thalidomide.
Topics: Consumer Product Safety; Humans; Leprosy; Peripheral Nervous System Diseases; Thalidomide | 1994 |
Safety of thalidomide.
Topics: Consumer Product Safety; Humans; Leprosy; Thalidomide | 1994 |
Thalidomide, a current teratogen in South America.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Leprostatic Agents; Leprosy; Male; Pre | 1996 |
[Suspected leprosy].
Topics: Adult; Aged; Aged, 80 and over; Dapsone; Diagnosis, Differential; Female; Humans; Leprostatic Agents | 1997 |
Thalidomide reconsidered.
Topics: Drug Approval; Humans; Leprostatic Agents; Leprosy; Thalidomide; United States; United States Food a | 1997 |
The problem with thalidomide's new incarnation.
Topics: Acquired Immunodeficiency Syndrome; Drug Approval; Humans; Leprosy; Neoplasms; Thalidomide; United S | 1998 |
Thalidomide's approval.
Topics: Drug Approval; Female; Humans; Leprosy; Thalidomide; United States | 1998 |
Thalidomide.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Inf | 1998 |
Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients.
Topics: Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; L | 2000 |
Thalidomide approved.
Topics: Drug Approval; Humans; Leprostatic Agents; Leprosy; Thalidomide; United States; United States Food a | 1998 |
Thalidomide's long and winding road.
Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Drug Approval; Female; Health Services Access | 1998 |
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |
Management of sulphone-resistant lepromatous leprosy.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium leprae; Thalidomide | 1977 |
Immunofluorescence studies in reactional leprosy with relevance to treatment.
Topics: Fluorescent Antibody Technique; Humans; Leprosy; Thalidomide | 1978 |
Workshop on "chemotherapy of leprosy" at the Central Leprosy Teaching and Research Institute, Chengalpattu (Tamil Nadu) on 21 January 1978.
Topics: Clofazimine; Dapsone; Humans; India; Leprosy; Recurrence; Rifampin; Thalidomide | 1979 |
[Motor-conduction velocity of cubital nerves in patients with leprosy reactions. Summary of a 13-year observation series during thalidomide therapy].
Topics: Adult; Follow-Up Studies; Humans; Israel; Leprosy; Male; Neural Conduction; Thalidomide; Ulnar Nerve | 1979 |
Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine.
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Male; Recurrence; Steroids; | 1979 |
Serum and tissue lysozyme in leprosy.
Topics: Adolescent; Adult; Aged; Dapsone; Histiocytes; Humans; Leprosy; Middle Aged; Muramidase; Radiation-P | 1977 |
Significance of neutrophil activation in reactional lepromatous leprosy: effects of thalidomide in vivo and in vitro. Activation in adjuvant disease.
Topics: Arthritis; Arthritis, Experimental; Leprosy; Lymphocyte Activation; Neutrophils; Thalidomide | 1978 |
Lucio's phenomenon and diffuse nonnodular lepromatous leprosy.
Topics: Adult; Dapsone; Erythema Nodosum; Female; Humans; Ischemia; Leprosy; Lymphopenia; Male; Middle Aged; | 1978 |
The diagnosis and treatment of leprosy.
Topics: Biopsy; Clofazimine; Dapsone; Erythema Nodosum; Humans; Immunotherapy; Leprosy; Recurrence; Rifampin | 1976 |
Treatment of Hansen's disease.
Topics: Chloroquine; Clofazimine; Dapsone; Drug Resistance, Microbial; Erythema Nodosum; Humans; Leprosy; Pr | 1976 |
An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug.
Topics: Adolescent; Adult; Clofazimine; Humans; Leprosy; Male; Middle Aged; Recurrence; Thalidomide | 1976 |
Thalidomide in lepra reaction.
Topics: Dapsone; Humans; Leprosy; Thalidomide | 1975 |
The drug treatment of leprosy.
Topics: Acute Disease; Adrenal Cortex Hormones; Aniline Compounds; Clofazimine; Dapsone; Drug Therapy, Combi | 1975 |
[World survey on the use of thalidomide in leprosy reaction].
Topics: Drug Evaluation; Humans; Leprosy; Thalidomide | 1975 |
Use of thalidomide in leprosy.
Topics: Humans; Leprosy; Nervous System Diseases; Thalidomide | 1991 |
The management of reaction in leprosy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Aspirin; Benzenesulfonates; Chloroquine | 1989 |
Thalidomide in dermatology and leprosy.
Topics: Female; Humans; Leprosy; Male; Pregnancy; Skin Diseases; Thalidomide | 1985 |
Thalidomide and leprosy.
Topics: Humans; Leprosy; Nervous System Diseases; Thalidomide | 1985 |
The clinical significance of erythema nodosum.
Topics: Adult; Anti-Inflammatory Agents; Antigen-Antibody Complex; Coccidioidomycosis; Diagnosis, Differenti | 1986 |
Defective monocyte chemotaxis in active lepromatous leprosy.
Topics: Antibodies, Bacterial; Antigens, Bacterial; Chemotaxis, Leukocyte; Erythema Nodosum; Glycolipids; Hu | 1987 |
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission.
Topics: Adult; Antibodies, Bacterial; Antigen-Antibody Complex; Chronic Disease; Cyclosporins; Erythema Nodo | 1987 |
Supplies of thalidomide for use in leprosy.
Topics: Humans; Leprosy; Thalidomide | 1986 |
Supplies of thalidomide for use in leprosy.
Topics: Humans; Leprosy; Thalidomide | 1986 |
Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males.
Topics: Adult; Erythema Nodosum; Humans; Leprosy; Leukocyte Count; Middle Aged; T-Lymphocytes; Thalidomide | 1985 |
Thalidomide--effect on T cell subsets as a possible mechanism of action.
Topics: Adolescent; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; T-Lymphocytes; Thalidomide | 1985 |
Mechanisms of reactions in leprosy.
Topics: Acute Disease; Adrenal Cortex Hormones; Animals; Antibody Formation; Chronic Disease; Erythema Nodos | 1972 |
Treatment of erythema nodosum leprosum with thalidomide.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Erythema Nodosum; Female; Humans; Leprosy; Male; Recu | 1973 |
Treatment of erythema nodosum leprosum with thalidomide.
Topics: Axons; Biopsy; Erythema Nodosum; Humans; Leprosy; Peripheral Nervous System Diseases; Thalidomide | 1973 |
Letter: Thalidomide in erythema nodosum leprosum.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 1973 |
Letter: Thalidomide in erythema nodosum leprosum.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 1973 |
Letter: Thalidomine neuropathy and leprous neuritis.
Topics: Diagnosis, Differential; Humans; Hypesthesia; Leprosy; Mycobacterium leprae; Neuritis; Peripheral Ne | 1974 |
[Early diagnosis, therapy, and research in the control of leprosy].
Topics: Aniline Compounds; Drug Synergism; Europe; Humans; Hyperbaric Oxygenation; Isoniazid; Leprosy; Phena | 1970 |
[Thalidomide neuropathy in the late stage. A clinical documentation].
Topics: Aged; Female; Follow-Up Studies; Humans; Leprosy; Male; Middle Aged; Motor Neurons; Nerve Degenerati | 1973 |
B lymphocytes in lepromatous leprosy.
Topics: Adult; Aged; B-Lymphocytes; Dapsone; Fluorescent Antibody Technique; Humans; Immune Sera; Immunoglob | 1973 |
[Initial clinical results using new, experimentally developed therapeutic forms in leprosy].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Dapsone; Drug Therapy, Combination; Ethiopia; | 1973 |
[Current status of the medical treatment of Hansen's disease].
Topics: Glucocorticoids; Humans; Kanamycin; Leprosy; Rifampin; Sulfonamides; Sulfones; Thalidomide; Thiourea | 1972 |
The significance of nerve involvement in leprosy.
Topics: Biopsy; Cortisone; Humans; Leprosy; Neuritis; Paralysis; Peripheral Nerves; Sensation; Thalidomide | 1974 |
A trial of thalidomide in progressive lepra reactions.
Topics: Female; Humans; Leprosy; Male; Prednisolone; Thalidomide | 1966 |
WHO expert committee on leprosy.
Topics: Attitude to Health; BCG Vaccine; Dapsone; Disability Evaluation; Disease Models, Animal; Health Educ | 1970 |
[Hansen L: action of thalidomide on a severe outburst].
Topics: Adult; Humans; Leprosy; Male; Thalidomide | 1971 |
[Quadriplegia, in lepromatous leprosy previously cleared-up, diffuse polyneuritis which appeared in spite of 6 years of follow-up consolidating treatment with Sultirene alone].
Topics: Adolescent; Adult; Child; Follow-Up Studies; Humans; Leprosy; Male; Polyneuropathies; Quadriplegia; | 1971 |
[Thalidomide in the control of pain in leprotic neuritis].
Topics: Female; Humans; Leprosy; Male; Neuralgia; Neuritis; Pain; Thalidomide | 1966 |
Therapy of leprosy.
Topics: Aniline Compounds; Anti-Infective Agents; Humans; Imines; Leprosy; Phenazines; Sulfonamides; Sulfone | 1970 |
[Results of modern therapy of leprosy].
Topics: Communicable Disease Control; Drug Hypersensitivity; Humans; Leprosy; Sulfathiazoles; Sulfonamides; | 1969 |
[Thalidomide in the treatment of leprosy reactions. 3 years of experience in Mexico].
Topics: Adolescent; Adult; Child; Female; Humans; Leprosy; Male; Mexico; Middle Aged; Thalidomide | 1969 |
Iridocyclitis in lepra reaction treated with thalidomide.
Topics: Adult; Female; Humans; Leprosy; Male; Middle Aged; Thalidomide; Uveitis, Anterior | 1970 |
Phytohaemagglutinin-induced lymphocyte transformation in leprosy.
Topics: Asian People; Biopsy; China; Erythema Nodosum; Humans; India; Lectins; Leprosy; Lymphocyte Activatio | 1971 |
[Thalidomide and lepromatous leprosy reaction].
Topics: Adult; Female; Humans; Leprosy; Male; Middle Aged; Thalidomide | 1967 |
[Thalidomide in leprosy reactions].
Topics: Adult; Humans; Leprosy; Male; Middle Aged; Sex Factors; Thalidomide | 1967 |
[Failure of thalidomide treatment in a case of leprous erythema multiforme].
Topics: Adult; Erythema Multiforme; Humans; Leprosy; Male; Sulfamethoxypyridazine; Thalidomide | 1968 |
[2 cases of anti-reactive ineffectiveness of thalidomide treatment of leprosy].
Topics: Adult; Humans; Leprosy; Male; Middle Aged; Thalidomide | 1968 |
[Treatment of leprous reaction of the erythema nodosum type with thalidomide (N-phthalimidoglutarimide)].
Topics: Ectromelia; Erythema Nodosum; Female; Humans; Leprosy; Male; Pregnancy; Sex Factors; Thalidomide | 1968 |
Trials with thalidomide derivatives in leprosy reactions.
Topics: Adult; Female; Humans; Leprosy; Male; Middle Aged; Thalidomide | 1968 |
[Leprosy reactions and thalidomide].
Topics: Female; Humans; Leprosy; Male; Thalidomide | 1968 |
[Our experience in the therapy of leprous reactions with thalidomide].
Topics: Erythema Multiforme; Erythema Nodosum; Humans; Leprosy; Thalidomide | 1968 |
Hansenosis of the neurotrophic type.
Topics: Adult; Fever; Humans; Leprosy; Male; Nervous System Diseases; Skin; Sulfones; Thalidomide | 1969 |
Further observation with thalidomide in lepra reactions.
Topics: Adult; Female; Humans; Leprosy; Male; Middle Aged; Thalidomide | 1965 |
[Experiences with thalidomide in 2 patients with acute lepromatous leprosy reactions].
Topics: Humans; Leprosy; Male; Middle Aged; Thalidomide | 1966 |